Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality.


Journal

Current cardiology reports
ISSN: 1534-3170
Titre abrégé: Curr Cardiol Rep
Pays: United States
ID NLM: 100888969

Informations de publication

Date de publication:
12 2023
Historique:
accepted: 31 10 2023
medline: 26 1 2024
pubmed: 17 11 2023
entrez: 16 11 2023
Statut: ppublish

Résumé

According to the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Heart failure has been defined as a global pandemic leading to millions of deaths. Recent research clearly approved the beneficial effect of Coenzyme Q10 supplementation in treatment and prevention of cardiovascular disease in patients with heart failure in clinical trials but did not distinguish between the oxidised form CoQ10 and reduced form CoQH2 of Coenzyme Q10. The aim of this study is to determine differences in medical application of CoQ10 and CoQH2 supplementation and evaluate the efficacy of CoQ10 and CoQH2 supplementation to prevent cardiovascular disease in patients with heart failure. A PubMed search for the terms "ubiquinone" and "ubiquinol" was conducted, and 28 clinical trials were included. Our findings go along with the biochemical description of CoQ10 and CoQH2, recording cardiovascular benefits for CoQ10 and antioxidative and anti-inflammatory properties for CoQH2. Our main outcomes are the following: (I) CoQ10 supplementation reduced cardiovascular death in patients with heart failure. This is not reported for CoQH2. (II) Test concentrations leading to cardiovascular benefits are much lower in CoQ10 studies than in CoQH2 studies. (III) Positive long-term effects reducing cardiovascular mortality are only observed in CoQ10 studies. Based on the existing literature, the authors recommend CoQ10 instead of CoQH2 to treat and prevent cardiovascular disease in patients with heart failure.

Identifiants

pubmed: 37971634
doi: 10.1007/s11886-023-01992-6
pii: 10.1007/s11886-023-01992-6
pmc: PMC10811087
doi:

Substances chimiques

coenzyme Q10 EJ27X76M46
ubiquinol M9NL0C577Y
Ubiquinone 1339-63-5

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1759-1767

Informations de copyright

© 2023. The Author(s).

Références

Nutrition. 2019 Jan;57:133-140
pubmed: 30153575
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
JACC Heart Fail. 2014 Dec;2(6):641-9
pubmed: 25282031
Clin Investig. 1993;71(8 Suppl):S155-61
pubmed: 8241702
J Cardiothorac Vasc Anesth. 2008 Dec;22(6):832-9
pubmed: 18834786
Ann Vasc Surg. 2020 Apr;64:292-302
pubmed: 31629852
Am J Cardiol. 2007 May 15;99(10):1409-12
pubmed: 17493470
J Am Coll Cardiol. 2021 Feb 9;77(5):609-619
pubmed: 33538259
Cardiovasc Drugs Ther. 1998 Sep;12(4):347-53
pubmed: 9825179
Integr Med (Encinitas). 2021 Oct;20(5):26-30
pubmed: 34803537
PLoS One. 2016 Jul 01;11(7):e0157541
pubmed: 27367855
Cardiol J. 2019;26(2):147-156
pubmed: 30835327
Aging (Albany NY). 2020 Jul 31;12(15):15514-15531
pubmed: 32741773
Integr Med (Encinitas). 2021 Aug;20(4):24-28
pubmed: 34602873
Antioxidants (Basel). 2021 Jun 03;10(6):
pubmed: 34205085
Resuscitation. 2021 May;162:388-395
pubmed: 33577964
Int J Cardiol. 2013 Sep 1;167(5):1860-6
pubmed: 22626835
Mol Aspects Med. 1994;15 Suppl:s155-63
pubmed: 7752827
Eur J Clin Invest. 2013 Nov;43(11):1203-23
pubmed: 24102389
Mol Aspects Med. 1997;18 Suppl:S63-70
pubmed: 9266507
J Nutr. 2022 Jul 6;152(7):1666-1674
pubmed: 35348726
Mol Aspects Med. 1994;15 Suppl:s143-7
pubmed: 7752825
Am J Cardiol. 2022 Aug 1;176:79-88
pubmed: 35644694
Cardiovasc Res. 2023 Jan 18;118(17):3272-3287
pubmed: 35150240
Mol Biotechnol. 2007 Sep;37(1):31-7
pubmed: 17914161
Drug Des Devel Ther. 2019 Oct 21;13:3647-3655
pubmed: 31695332
Clin Investig. 1993;71(8 Suppl):S60-5
pubmed: 8241707
J Gerontol A Biol Sci Med Sci. 2012 Jan;67(1):3-10
pubmed: 22016358
Med Sci Monit. 2014 Nov 06;20:2183-8
pubmed: 25375075
J Am Coll Nutr. 2001 Dec;20(6):591-8
pubmed: 11771674
Diabetes Care. 2008 Aug;31(8):1502-9
pubmed: 18487480
Eur J Nutr. 2022 Sep;61(6):3135-3148
pubmed: 35381849
Integr Med (Encinitas). 2021 Dec;20(6):24-28
pubmed: 35250400
Kardiologiia. 2013;53(8):40-3
pubmed: 24087999
Drug Discov Ther. 2019;13(1):38-46
pubmed: 30880321
Clin Investig. 1993;71(8 Suppl):S134-6
pubmed: 8241697
Ann Thorac Surg. 1994 Nov;58(5):1427-32
pubmed: 7979670
Nutrients. 2021 Apr 17;13(4):
pubmed: 33920725
PLoS One. 2015 Dec 01;10(12):e0141641
pubmed: 26624886
Antioxidants (Basel). 2020 May 05;9(5):
pubmed: 32380795
Drugs R D. 2022 Mar;22(1):25-33
pubmed: 34826125
Mitochondrion. 2007 Jun;7 Suppl:S51-61
pubmed: 17482887
PLoS One. 2018 Apr 11;13(4):e0193120
pubmed: 29641571
Clin Cardiol. 2004 May;27(5):295-9
pubmed: 15188947
Cardiovasc Ther. 2016 Aug;34(4):254-60
pubmed: 27214383
Am J Cardiovasc Drugs. 2020 Aug;20(4):363-372
pubmed: 31713723
Nutrients. 2022 Aug 15;14(16):
pubmed: 36014852
PLoS One. 2015 Sep 16;10(9):e0137680
pubmed: 26375288

Auteurs

Johannes-Paul Fladerer (JP)

Institute of Pharmaceutical Sciences, University of Graz, Beethovenstraße 8, 8010, Graz, Austria. johannes.fladerer@uni-graz.at.
Apomedica Pharmazeutische Produkte GmbH, Roseggerkai 3, 8010, Graz, Austria. johannes.fladerer@uni-graz.at.

Selina Grollitsch (S)

Institute of Pharmaceutical Sciences, University of Graz, Beethovenstraße 8, 8010, Graz, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH